Date: 2012-11-12
Type of information: R&D agreement
Compound: new medicines
Company: GSK (UK) Imagine Institute (France)
Therapeutic area: 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one
Type agreement: R&D
Action mechanism:
Disease: Netherton syndrome
Details: * On November 12, 2012, GSK and Imagine Institute, a french translational research institute dedicated to genetic diseases (Inserm/ University Paris Descartes) have agreed a collaborative partnership to discover and develop medicines with the potential to treat Netherton Syndrome, a rare, genetically inherited, severe skin disorder. Under the terms of the agreement initiated and brokered by Inserm Transfert, the alliance will seek to build on the work of Prof. Alain Hovnanian at the Necker Children Hospital in Paris following significant breakthroughs in the understanding of the underlying disease mechanisms guided by the identification of the disease gene. Work on the project will be carried out within GSK and both at the Genetics Department and Inserm unit U781, Necker Hospital, Paris. The collaboration will operate as a single integrated team, combining Prof. Hovnanian’s deep disease and biology understanding with GSK\'s expertise in drug discovery and development.
Netherton syndrome is one of the most severe genetic skin diseases of children and adults. No specific treatment is currently available, but the recent progress made in the disease pathogenesis allow for the development of specific new drugs targeting key biological events. These molecules have a strong therapeutic potential and are a promise for a better treatment of patients suffering from this devastating condition.
This alliance is the first of GSK\'s Discovery Partnerships with Academia (DPAc) projects to run outside of the UK.
Financial terms: The University Hospital Institute IHU Imagine and Inserm will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration. Inserm Transfert will provide both parties with alliance management.
Latest news:
